CCM
FULC icon

Catalio Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Catalio Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-201,301
Closed -$2.28M – 44
2025
Q4 		$2.28M Buy
+201,301
New +$2.05M 0.4% 36
2025
Q3 		– Sell
-188,304
Closed -$1.3M – 41
2025
Q2 		$1.3M Sell
188,304
-13,835
-7% -$74K 0.27% 32
2025
Q1 		$582K Buy
+202,139
New +$742K 0.14% 32

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Catalio Capital Management's FULC Position: Q1 2026 in Review

Catalio Capital Management sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 201,301 shares — an estimated $2.28M sold.

Catalio Capital Management first reported a position in FULC in Q1 2025 and held it in 3 quarters. The position peaked at $2.28M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Catalio Capital Management reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Catalio Capital Management sold 201,301 Fulcrum Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Catalio Capital Management first reported a position in Fulcrum Therapeutics in Q1 2025 and held it in 3 quarters.
  • Catalio Capital Management's Fulcrum Therapeutics position peaked at $2.28M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.